市場調查報告書
商品編碼
1368726
止血產品市場規模 - 按產品、按應用、按最終用途以及 - 到 2032 年的全球預測Hemostasis Products Market Size - By Product, By Application, By End-use - Global Forecast to 2032 |
由於全球事故和創傷病例發生率不斷上升,全球止血產品市場將於 2023 年至 2032 年間以顯著的年複合成長率擴張。據國際勞工組織稱,全球每年約有 230 萬名男性和女性因工傷事故或疾病而喪生,相當於每天有 6,000 多人死亡。每年,全世界都會發生約 3.4 億起職業事故。止血產品,例如凝血因子和止血劑,對於緊急情況下控制出血至關重要。隨著事故和外傷的增加,對這些產品的需求不斷上升,因為它們對於拯救生命和防止過度失血至關重要,從而促進了市場的擴張。
整個止血產品市場根據產品、應用、最終用途和地區進行分類。
不輸止血產品產業將在 2023-2032 年顯著成長。不熔止血產品由於其在各種醫療手術和創傷情況下能夠快速控制出血的有效性而受到很高的需求。這些產品,例如凝血因子和止血劑,為最大限度地減少失血、降低併發症風險和改善患者預後提供了關鍵的解決方案。隨著手術、創傷病例和醫療干涉數量的增加,對不輸止血產品的需求持續成長,推動市場成長。
到2032 年,血友病細分市場可能會累積顯著的止血產品市場。由於止血產品在控制這種出血性疾病方面發揮著至關重要的作用,因此擴大用於血友病治療。血友病患者缺乏必需的凝血因子,而止血產品,包括因子濃縮物和凝血因子替代療法,有助於控制和預防過度出血。隨著診斷、治療和患者護理的改善,血友病治療中對這些產品的需求不斷增加,從而促進了它們在該醫療領域的利用率的提高。
由於多種因素,歐洲止血產品產業正在以顯著的速度擴張。該地區人口老化以及需要止血干涉的疾病盛行率較高,促進了市場成長。醫療技術和外科手術的進步增加了對這些產品的需求。此外,嚴格的醫療法規和人們對止血療法的認知不斷提高也促進了止血療法的使用。這些綜合因素為該行業在歐洲的擴張創造了有利的環境。
Global Hemostasis Products Market will expand at a notable CAGR between 2023 and 2032, driven by the growing incidence of accidents and trauma cases across the globe. According to the ILO, approximately 2.3 million men and women globally lose their lives due to work-related accidents or illnesses each year, equating to more than 6,000 daily fatalities. Each year, the world witnesses roughly 340 million occupational accidents. Hemostasis products, such as clotting factors and hemostatic agents, are critical for controlling bleeding in emergencies. With a rise in accidents and traumatic injuries, the demand for these products is on the upswing, as they are essential for saving lives and preventing excessive bleeding, contributing to the market's expansion.
The overall hemostasis products market is segregated based on product, application, end-use, and region.
Infusible hemostasis products industry will register significant growth throughout 2023-2032. Infusible hemostasis products are in high demand due to their effectiveness in rapidly controlling bleeding in various medical procedures and trauma situations. These products, such as clotting factors and hemostatic agents, offer a critical solution for minimizing blood loss, reducing the risk of complications, and improving patient outcomes. With an increasing number of surgeries, trauma cases, and medical interventions, the demand for infusible hemostasis products continues to rise, driving market growth.
The hemophilia segment could accumulate a notable hemostasis products market share by 2032. Hemostasis products are increasingly utilized for hemophilia treatment due to their vital role in managing this bleeding disorder. Hemophilia patients lack essential clotting factors, and hemostasis products, including factor concentrates and clotting factor replacement therapies, help control and prevent excessive bleeding. With improved diagnosis, treatment access, and patient care, the demand for these products in the management of hemophilia is on the rise, contributing to their increased utilization in this medical field.
Europe hemostasis products industry is expanding at a noticeable pace due to several factors. The region's aging population, with a higher prevalence of conditions requiring hemostasis intervention, contributes to market growth. Advances in medical technology and surgical procedures increase the demand for these products. Additionally, stringent healthcare regulations and rising awareness of hemostasis therapies promote their use. These combined factors create a conducive environment for the industry's expansion in Europe.